A phase I/II study of the protease inhibitor Ritonavir in children with human immunodeficiency virus infection

Pediatrics

Volumn 101, Issue 3 I, 1998, Pages 335-343

  Mueller, Brigitta U ^a,g   Nelson Jr, Robert P ^b   Sleasman, John ^c   Zuckerman, Judy ^a   Heath Chiozzi, Margo ^d   Steinberg, Seth M ^a   Balis, Frank M ^a   Brouwers, Pim ^a   Hsu, Ann ^d   Saulis, Rima ^d   Sei, Shizuko ^a   Wood, Lauren V ^a   Zeichner, Steve ^a   Katz, T Teresa K ^d   Higham, Colleen ^a   Aker, Diane ^a   Edgerly, Maureen ^a   Jarosinski, Paul ^e   Serchuck, Leslie ^a   Whitcup, Scott M ^f   Pizzuti, David ^d   Pizzo, Philip A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d ABBOTT LABORATORIES   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL EYE INSTITUTE   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CD4 cells; Child; HIV RNA; HIV 1; Pharmacokinetics; Protease inhibitor

Indexed keywords

DIDANOSINE; RITONAVIR; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; MALE; RITONAVIR; VIRAL LOAD; ZIDOVUDINE;

EID: 0031905451     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.101.3.335     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. AIDS among children -United States, 1996. MMWR. 1996;45:1005-1010
2. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HV-1 infection. N Engl J Med. 1995;333:1534-1539
3. Kempf DJ, Marsh KC, Paul DA, et al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1991;35:2209-2214
4. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA. 1995;92:2484-2488
5. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528-1533
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586
8. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017
9. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43:1-12
10. Brouwers P, Belman A, Epstein L. Central nervous system involvement: manifestations, evaluation, and pathogenesis. In: Pizzo PA, Wilfert CA, eds. Pediatric AIDS. The Challenge of HIV Infection in Infants, Children, and Adolescents. Baltimore, MD: Williams & Wilkins; 1994:433-455
11. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfleld L, Kwok S. Rapid and simple PCR assay for quantisation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300
12. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr. 1998. In press
13. Brouwers P, Mohr E. A metric for the evaluation of change in clinical trials. Clin Neuropharmacol. 1989;12:129-133
14. Centers for Disease Control and Prevention. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1993;41:1-19
15. Whitcup SM, Dastgheib K, Nussenblatt RB, Walton RC, Pizzo PA, Chan C-C. A clinicopathologic report of the retinal lesions associated with didanosine. Arch Ophthalmol. 1994;112:1594-1598
16. Palumbo PE, Kwok S, Wesley Y, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr. 1995;126:592-595
17. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther. 1979; 24:316-323
18. Levy RH, Lai AA, Dumain MS. Time-dependent kinetic IV: pharmacokinetic theory of enzyme induction. J Pharm Sci. 1979;68:398-399
19. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;324:137-144
20. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics. 1994;94:724-731
21. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus infection. N Engl J Med. 1997;336:1343-1349
22. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics. 1996;97:886-890
23. Merrill DP, Moonis M, Chou T-C, Hirsch MS. Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996;173:355-364
24. Husson RN, Mueller BU, Farley M, et al. Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Pediatrics. 1994;93:316-322
25. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1996;174:16-25
26. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. AIDS. 1996;10:859-865
27. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HTV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170
28. Saag MS, Crain MJ, Decker WD, et al. High-level viremia in adults and children infected with human immunodeficiency virus: relation to stage of disease and CD4+ lymphocyte levels. J Infect Dis. 1991;164:72-80
29. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med. 1996;2:625-629
30. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995;69:701-706
31. Schmit J-C, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 1996;10:995-999
32. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 1996; 2:760-766